Mark Purcell
Stock Analyst at Morgan Stanley
(1.34)
# 3,640
Out of 5,152 analysts
6
Total ratings
66.67%
Success rate
-6.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $45.00 | +28.89% | 2 | Sep 8, 2025 | |
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $161.01 | -29.20% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $55.27 | -20.39% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $197.52 | -56.97% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $39.07 | +207.14% | 1 | Jan 23, 2024 |
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $45.00
Upside: +28.89%
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $161.01
Upside: -29.20%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $55.27
Upside: -20.39%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $197.52
Upside: -56.97%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $39.07
Upside: +207.14%